With the recent approval of several drugs for the management of chronic hepatitis B, the proper diagnosis and classification of this disease is necessary to determine if therapy is needed and what the best treatment options are. The diagnosis of chronic hepatitis B relies on serological testing, and disease stage is further characterized with HBV DNA levels and an assessment of liver disease through biopsy or non-invasive methods. A regular screening protocol is necessary for patients with chronic hepatitis B to monitor the development of cirrhosis and hepatocellular carcinoma. Patients receiving treatment also need regular monitoring for response to determine if a different therapeutic regimen is needed or if drug-resistant variants are being selected. This review discusses the various tests for hepatitis B diagnosis and for monitoring disease progression and treatment response. In addition, noninvasive methods for classifying liver disease stage are discussed, as are special considerations that are needed for individuals coinfected with HIV.
References
1.
McGovernB.H.The epidemiology, natural history and prevention of hepatitis B: implications of HIV coinfection.Antivir Ther2007; 12Suppl 3: H3–H13.
2.
MizuochiT., OkadaY., UmemoriK., MizusawaS., YamaguchiK.Evaluation of 10 commercial diagnostic kits for in vitro expressed hepatitis B virus (HBV) surface antigens encoded by HBV of genotypes A to H.J Virol Methods2006; 136: 254–256.
3.
WeberB.Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact.J Clin Virol2005; 32: 102–112.
4.
DentingerC.M., McMahonB.J., ButlerJ.C.Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth.Pediatr Infect Dis J2005; 24: 786–792.
5.
ZanettiA.R., MarianoA., RomanoL.Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.Lancet2005; 366: 1379–1384.
6.
MannsM.P., SchulerA.Risk of hepatitis A superinfection in patients with underlying liver disease.Acta Gastroenterol Belg1998; 61: 206–209.
7.
ChenC.J., YangH.I., SuJ.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.JAMA2006; 295: 65–73.
8.
IloejeU.H., YangH.I., SuJ., JenC.L., YouS.L., ChenC.J.Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.Gastroenterology2006; 130: 678–686.
JanssenH.L., van ZonneveldM., SenturkH.Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.Lancet2005; 365: 123–129.
11.
YuM.W., YehS.H., ChenP.J.Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men.J Natl Cancer Inst2005; 97: 265–272.
12.
SumiH., YokosukaO., SekiN.Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease.Hepatology2003; 37: 19–26.
13.
KeeffeE.B., DieterichD.T., HanS.H.A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update.Clin Gastroenterol Hepatol2006; 4: 936–962.
14.
HussainM., ChuC.J., SablonE., LokA.S.Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants.J Clin Microbiol2003; 41: 3699–3705.
15.
MaharajB., MaharajR.J., LearyW.P.Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver.Lancet1986; 1: 523–525.
16.
OngT.Z., TanH.J.Ultrasonography is not reliable in diagnosing liver cirrhosis in clinical practice.Singapore Med J2003; 44: 293–295.
17.
FoucherJ., CasteraL., BernardP.H.Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations.Eur J Gastroenterol Hepatol2006; 18: 411–412.
18.
de LedinghenV., DouvinC., KettanehA.Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients.J Acquir Immune Defic Syndr2006; 41: 175–179.
19.
FoucherJ., ChanteloupE., VergniolJ.Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study.Gut2006; 55: 403–408.
20.
MontazeriG., EstakhriA., MohamadnejadM.Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B.BMC Gastroenterol2005; 5: 32.
21.
MyersR.P., TainturierM.H., RatziuV.Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.J Hepatol2003; 39: 222–230.
22.
WaiC.T., ChengC.L., WeeA.Non-invasive models for predicting histology in patients with chronic hepatitisB Liver Int2006; 26: 666–672.
23.
LebensztejnD.M., SkibaE., Sobaniec-LotowskaM., KaczmarskiM.A simple noninvasive index (APRI) predicts advanced liver fibrosis in children with chronic hepatitis B.Hepatology2005; 41: 1434–1435.
24.
HuiC.K., CheungW.W., ZhangH.Y.Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy.Gastroenterology2006; 131: 59–68.
25.
ChamorroA.J., CasadoJ.L., BellidoD., MorenoS.Reactivation of hepatitis B in an HIV-infected patient with antibodies against hepatitis B core antigen as the only serological marker.Eur J Clin Microbiol Infect Dis2005; 24: 492–494.
26.
LiY.H., HeY.F., JiangW.Q.Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.Cancer2006; 106: 1320–1325.
OsiowyC., VilleneuveJ.P., HeathcoteE.J., GilesE., BorlangJ.Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2).J Clin Microbiol2006; 44: 1994–1997.
29.
DoutreloigneJ., Van AsscheE.S.E.Analysis of drug resistant mutations associated with entecavir, tenofovir, adefovir dipivoxil treatment using a novel line probe assay.42nd European Association for the Study of the Liver. 11–15 April 2007, Barcelona, Spain. Abstract 515.
30.
LokA.S., ZoulimF., LocarniniS.Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay.J Clin Microbiol2002; 40: 3729–3734.
FilippiniP., CoppolaN., PisapiaR.Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy.AIDS2006; 20: 1253–1260.
33.
LocarniniS., WarneN.Major causes of antiviral drug resistance and implications for treatment of HBV monoinfection and coinfection with HIV.Antivir Ther2007; 12Suppl 3: H15–H23.
34.
YangH., QiX., SabogalA., MillerM., XiongS., DelaneyW.E.Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV.Antivir Ther2005; 10: 625–633.
35.
MatthewsG.V., BartholomeuszA., LocarniniS.Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.AIDS2006; 20: 863–870.
36.
ThioC.L., SeabergE.C., SkolaskyR.L.HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS).Lancet2002; 360: 1921–1926.
37.
ColinJ.F., Cazals-HatemD., LoriotM.A.Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.Hepatology1999; 29: 1306–1310.
